Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Case-control Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 150
- Locations
- 2
- Primary Endpoint
- Prevalence of Urine Congophilia Using Congo Red Test GV-005
Study Overview
Brief Summary
A case-control study will evaluate the clinical utility of the Congo Red test GV-005 in following women with a clinical diagnosis of preeclampsia and clinically healthy women in the postpartum period
Detailed Description
A case-control study (n=150) will evaluate the clinical utility of the Congo Red test GV-005 in following women with a clinical diagnosis of preeclampsia and clinically healthy women in the postpartum period. Women with preeclampsia (n=100) (cases) and clinically healthy women (n=50)(controls) who are hospitalized postpartum will be recruited for the trial. All women will be asked to provide a urine sample. Samples will be collected daily during a woman's hospitalization. The Congo Red test GV-005 and a standard urine dipstick proteinuria test will be performed by a lab technician within 72 hours of sample collection. The purpose of this research is to evaluate progression of urine congophilia postpartum by following patients diagnosed with preeclampsia and clinically healthy women.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 64 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Postpartum
- •Clinical diagnosis of preeclampsia (severe, mild or superimposed) including eclampsia (n=100) OR Clinically healthy (n=50)
- •Eligible to consent for research
- •Agree to comply with study procedures
- •Able to give informed consent
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Prevalence of Urine Congophilia Using Congo Red Test GV-005
Time Frame: within 72 hours of urine sample collection
Prevalence of urine congophilia using Congo Red test GV-005
Secondary Outcomes
No secondary outcomes reported
